Testing Lower Radiation Doses for Diffuse Large B-Cell Lymphoma
Compares a lower radiation dose with standard dose in lymphoma patients.
Plain-language title generated from the registry record
Registry title: Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.
Key facts
- Where
- Mumbai, IndiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT02964858, who can take part
Where in India
- Tata Memorial CenterMumbai, IndiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tata Memorial Hospital
- Trial code
- NCT02964858
- Record updated
- 11 April 2025
- Original description
The purpose of this study is to compare standard dose radiation of 45 Gray(Gy) in 25 fractions in Non Hodgkin's Lymphoma- Diffuse Large B cell Lymphoma (NHL-DLBCL) to that of 36 Gy in 20 fractions.Read full original descriptionShow less
Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma (DOBL) - A Randomised Phase III Non- Inferiority Trial.
The purpose of this study is to compare standard dose radiation of 45 Gray(Gy) in 25 fractions in Non Hodgkin's Lymphoma- Diffuse Large B cell Lymphoma (NHL-DLBCL) to that of 36 Gy in 20 fractions.
The role of radiation in NHL-DLBCL has been addressed in large cooperative trials showing improvement in overall survival and progression free survival with combined modality treatment. The doses of radiation used in these trials are heterogeneous ranging from 30-55 Gray(Gy). There is uncertainty about the optimal dose of radiation needed in aggressive lymphomas. A dose response phenomenon is known in Non- Hodgkin's Lymphoma. Late effects of higher dose radiation in the form of higher risk of stroke, myocardial infarction, thyroid abnormalities and secondary breast cancer are being increasingly identified. Hence it is essential to optimize the dose of radiotherapy for lower toxicity without compromising on efficacy.
Inclusion: Histological Diagnosis of NHL- DLBCL; Eligible for RT after R-CHOP; ECOG 0-3; 18 - 65 years; Stage I-IV; Patients should receive at least 4 cycles of R-CHOP chemotherapy; Patients with all extranodal disease except the ones mentioned in the exclusion criteria; Able to understand and willing to provide informed consent for participation in the trial.
Exclusion: Prior history of chemotherapy; Prior history of radiotherapy; HIV positive status; Relapse or progression of disease during chemotherapy; Systemic lymphomas with CNS involvement; Primary extranodal Testicular Lymphomas; Primary extranodal central nervous system (CNS) Lymphomas; Primary extranodal Stomach DLBCL; Primary extranodal Intestinal DLBCL; Patients >3 extranodal sites.